3.2. Colostrum Efficacy in Mitigating Frequency of URTIs
URTIs
SECONDARY
To assess the efficacy of colostrum (COL) in reducing the frequency of URTIs, we analyzed the number of days in which participants observed any symptoms of URTIs based on weekly reports over the entire experiment period (107 days). Analyzing all participants together, we found an insignificantly lower number of days with any URTIs symptoms in subjects receiving colostrum compared to those receiving placebo (COL: 6 (2–15.25) vs. PBO: 9 (2–18.5); When we summed up the URTIs symptoms severity results and analyzed them collectively in all trial participants within both intervention groups (COL and PBO) over the entire observation period, these scores were higher in the placebo group, but insignificantly (COL: 9 (1–22.5) vs. PBO: 11 (2.75–23.75; The frequency of days with any URTIs symptoms, as reported weekly, and severity scores obtained from daily surveys were also analyzed by two-way analyses of variance. Data divided into periods of the trial (supplementation—days 1–45, no supplementation—days 46–86 and secondary supplementation plus observation in the final two weeks—days 87–107) are presented in 